#NephJC Transcript

Healthcare social media transcript of the #NephJC hashtag.
().
See #NephJC Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
Ana Maria Matias @AMCMA6
RT @hswapnil: @CJASN The #NephJC discussion of the original commentary https://t.co/FpzVzs0T3l from @XPOTASN
GlomCon @GlomCon
Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a glombastic discussion! https://t.co/SKZJf7adSv
Xavier F. Vela @xaviervel
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Swapnil Hiremath, MD, MPH @hswapnil
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Marta Garrido @martiponi
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Joel Topf, MD FACP @kidney_boy
@AJKDonline Of note: We noticed the mistake of the microalbumin:cr ratio. The AJKD infographic has it right, both the manuscript and #NephJC are wrong.
Fra Ian 🇪🇺 @caioqualunque
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Pablo Garcia @PabloGarciaMD
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Mary Romero, MD @maryross86
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Michael Arnold MDPhD @marnold_pedpath
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Basu Gopal @BasuNephro
Avacopan - C5a receptor antagonist in ANCA vasculitis https://t.co/3xZBfti3oc
NBLU: Renal Leaders @NBLUniv
@Nephro_Sparks on #nephJC #NBLUniv https://t.co/BqN3O5lzZ5
NBLU: Renal Leaders @NBLUniv
Visual abstracts #nephJC #NBLUniv https://t.co/agFgmCGgPj
Kevin J. Fowler @gratefull080504
Just finished the @JASN_News article on #vasculitis with investigative medication I will be at #nephJC as long as I can contribute @NephJC https://t.co/WJ7MORQC5A
Kevin J. Fowler @gratefull080504
@VasculitisFound: are you joining us tonight at #nephJC ? Hope so! https://t.co/WJ7MORQC5A
Matt Sparks @Nephro_Sparks
RT @NBLUniv: Visual abstracts #nephJC #NBLUniv https://t.co/agFgmCGgPj
Michelle Rheault @rheault_m
Complement cascade, ANCA associated vasculitis, and randomized controlled trials...Oh my. Tonight at 9 EST! #NephJC https://t.co/qL7ai892jB
Cathy Quinlan @KidneyCathy
RT @rheault_m: Complement cascade, ANCA associated vasculitis, and randomized controlled trials...Oh my. Tonight at 9 EST! #NephJC https://…
Nephrology Jrnl Club @NephJC
Counting down to Avacopan in ANCA vasculitis. https://t.co/dHatt7iWPv #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
RT @rheault_m: Complement cascade, ANCA associated vasculitis, and randomized controlled trials...Oh my. Tonight at 9 EST! #NephJC https://…
Swapnil Hiremath, MD, MPH @hswapnil
RT @RheumJC: This Tues & Wed, #NephJC will be discussing the C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.…
Nephrology Jrnl Club @NephJC
Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/ebwCRF1adF
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/e…
Cathy Quinlan @KidneyCathy
Taking a turn at moderating this tonight and feeling surprisingly nervous! #nephjc https://t.co/8Ie0ZuhJyU
Cathy Quinlan @KidneyCathy
Excellent summary and still time to read and participate in #nephjc - starts in 35 minutes https://t.co/VhA6nWQXYy
Cathy Quinlan @KidneyCathy
one book that brings together donor/recipient/doctor views? Yes - check out #100sInterlacedFingers #NephJC https://t.co/H4y0dAXmRH
Gerardo Alfaro @gerardoalfaromd
RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/e…
Dr. Paul Sufka @psufka
RT @toates_19: I wrote the summary for our #NephJC on the CLEAR study in #vasculitis https://t.co/oeSvlMRvEw
Rheum Journal Club @RheumJC
RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/e…
Dr. Paul Sufka @psufka
RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/e…
Cathy Quinlan @KidneyCathy
#nephJC kicks off in 5, I'm set up and ready to go - do you think I have enough screens? https://t.co/rIroxSv9d9
Michelle Rheault @rheault_m
@KidneyCathy You'll do great! At the end your head will be spinning. #NephJC
Joel Topf, MD FACP @kidney_boy
Wait Cathy's running this? Awesome! #nephjc
Nikhil Shah @dr_nikhilshah
@KidneyCathy All set, best luck. Get your coffee first!! Quick. #nephjc https://t.co/7PWvMT41UR
Nephrology Jrnl Club @NephJC
It’s 11am in Melbourne and time for #nephjc Let’s get this party started!
Cathy Quinlan @KidneyCathy
It’s 11am in Melbourne and time for #nephjc Let’s get this party started! https://t.co/NdpnXH8a3q
Joel Topf, MD FACP @kidney_boy
RT if you had a crush on Olivia Newton John. Fav if you are too young to know who the hell that is. #nephjc
Nephrology Jrnl Club @NephJC
Need a quick catch up before diving into #nephjc – read the summary from @toates_19 https://t.co/ebwCREJyP5
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Edgar Lerma, Chicago-based Nephrologist #NephJC https://t.co/7Yb9ocrH0S
Joel Topf, MD FACP @kidney_boy
Tom knocked it out of the park MT @NephJC: Need a quick catch up? – read the summary from @toates_19 https://t.co/s3LZHR2nJA #nephjc
Joel Topf, MD FACP @kidney_boy
hey Edgar, nice to see you. How have you been? #nephjc
Poyan Mehr @poyanmehr
Ali Poyan Mehr from Boston #nephjc
Kevin J. Fowler @gratefull080504
@gratefull080504 : joining the #nephJC chat from #Detroit tonight Enjoyed reviewing the JASN article ! https://t.co/rvUodmxC3l
Michelle Rheault @rheault_m
@kidney_boy I've watched Grease approximately 800 times #nephJC. I wanted to be her. https://t.co/mnDhvPInJf
Nephrology Jrnl Club @NephJC
We recommend using https://t.co/rFoH4MEbaU or TChat.io to follow the #nephjc chat. See a how to guide here: http//www.nephjc.com/how-to/
Anitha Vijayan @VijayanMD
Anitha Vijayan @WUNephrology. No COI #NephJC
Joel Topf, MD FACP @kidney_boy
It's like being on the Nebuchadnezzar from the Matrix https://t.co/oSifuU5q9B
Nephrology Jrnl Club @NephJC
Remember to add #NephJC to every tweet you want to be part of the discussion and part of the recorded journal club
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@kidney_boy Just hangin' #NephJC https://t.co/lKEwY4oA3h
Michelle Rheault @rheault_m
@NephJC Michelle Rheault here. Ped Neph UMN. Lurking tonight. #Nephjc can't compete with ice cream and balloon animals at KidFest https://t.co/ssAcJ2N8zH
Nephrology Jrnl Club @NephJC
Welcome to #NephJC please introduce yourself and declare any conflict of interests (COI) even if you’re only planning on lurking
Nephrology Jrnl Club @NephJC
I’m Cathy Quinlan. I will be hosting and tweeting as @KidneyCathy & @KidGenAustralia. Paed neph & clinician researcher in Melbourne. #NephJC
Bea Concepcion @KidneyBea_n
Hello! Bea Concepcion #NSMC 2017 @VUMCKidney, No COI #nephjc
Cathy Quinlan @KidneyCathy
I’m Cathy Quinlan. Tweeting as @KidneyCathy & @KidGenAustralia. No COI as not important enough (yet) #NephJC
Joel Topf, MD FACP @kidney_boy
Hey Bea and Anitha, thanks for coming #nephjc
Nephrology Jrnl Club @NephJC
@KidneyBea_n @VUMCKidney Welcome to #NephJC and thanks for joining us!
Hector Madariaga @HecmagsMD
Hector Madariaga. No COI. From #PatriotsNation. Hi, everyone! #NephJC https://t.co/MKv6wFK0Ae
Nephrology Jrnl Club @NephJC
Hi @edgarvlermamd thanks for joining #nephjc
Kevin J. Fowler @gratefull080504
@gratefull080504 : COI: Protalix Biotherapeutics #nephJC https://t.co/cecIl0dHWh
Nephrology Jrnl Club @NephJC
Hi @HecmagsMD thanks for joining #nephjc
Nephrology Jrnl Club @NephJC
Hi @gratefull080504, looking forward to your insights! #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Arvind Canchi 🇮🇳 @arvindcanchi
#NephJC Arvind Canchi Nephrologist from Bangalore. No coi.
Dr. Paul Sufka @psufka
#nephjc Paul Sufka. Rheumatologist from St Paul, MN. Thanks for inviting the #RheumJC folks! COI: trying to put our 4yo to bed.
Nephrology Jrnl Club @NephJC
Welcome to #NephJC even if you’re only planning on lurking, please introduce yourself – it’s nice to know you’re there!
Joel Topf, MD FACP @kidney_boy
Hey Hector, I was talking to Howard, you up for another round of Fantasy Football? #nephjc
Silvi Shah, MD, MS @silvishah
Hi this is Silvi from Cincinnati #NephJC
Joel Topf, MD FACP @kidney_boy
Hi Silvi, thanks for coming #nephjc
Hector Madariaga @HecmagsMD
@KidneyCathy Hi Cathy. Please stay away from water! Hope all is well 😜 @kidgenaustralia #nephjc
Nephrology Jrnl Club @NephJC
Remember one of the core goals of #nephJC is to build a personal learning network so make sure to hit the follow button. https://t.co/kcyNd6P5n4
kevoooo @kevo00o
@NephJC #nephJC hey guys, 3rd year IM resident year. Just gonna be lurkin' and learnin' https://t.co/plrSXfgsMY
Kevin J. Fowler @gratefull080504
@NephJC thank you @NephJC #nephJC
kevoooo @kevo00o
@NephJC #nephJC hey guys, 3rd year IM resident here. Just gonna be lurkin' and learnin' https://t.co/w1c44MINXi
Hector Madariaga @HecmagsMD
@kidney_boy absolutely! I'm in. I hope to draft Jay Cutler #nephjc
Nephrology Jrnl Club @NephJC
Diving straight into the methodology - what did you think of the study design? Lots of potential criticism of parallel groups. #nephjc
Gates Colbert, MD @DoctorGates
Dallas based Nephrologist. Frequent ANCA vasculitis treater. #Plasmapheresis #NSMC2017 No COI #nephjc
Pablo Garcia @PabloGarciaMD
Pablo Garcia New Brunswick, NJ. #NSMC intern 2017. No CoI. #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Nephrology Jrnl Club @NephJC
@kevo00o @NephJC great to have you here - remember to hit the follow button! #nephjc
Sanjeev Nair @Nair_Sanj
Sanjeev Nair from Chennai. No CoI. #nephjc
Nephrology Jrnl Club @NephJC
Terrific summary (as always) from #nephpearls #nephjc https://t.co/FRGZuStKR5
Basu Gopal @BasuNephro
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Basu Gopal @BasuNephro
RT @rheault_m: Complement cascade, ANCA associated vasculitis, and randomized controlled trials...Oh my. Tonight at 9 EST! #NephJC https://…
Cathy Quinlan @KidneyCathy
Lots for neph to learn from rheum community especially their use of standardised outcomes @song_initiative #nephjc
Anna Burgner MD MEHP @anna_burgner
Hey all! Sorry I'm late! Clinical nephrologist @VUMCKidney with no coi #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Nephrology Jrnl Club @NephJC
@anna_burgner @VUMCKidney Hi Anna - really just getting started! #nephjc
kevoooo @kevo00o
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Sanjeev Nair @Nair_Sanj
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Michelle Rheault @rheault_m
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Nephrology Jrnl Club @NephJC
As before - really don't need to look anywhere else #nephpearls #nephjc https://t.co/V19OnM8ckc
Poyan Mehr @poyanmehr
@NephJC i thought the study design seems relatively standard for a phase II trial. #nephjc
Kevin J. Fowler @gratefull080504
Do all #patients with #vasculitis have progress to #ESRD ? #nephJC
Poyan Mehr @poyanmehr
@NephJC but the nature of that purpose doesn't come across in the manuscript #nephjc
Nephrology Jrnl Club @NephJC
Does anyone want to weigh in on the parallel group comparison methodology? #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD
J. Brian Byrd, MD, MS 🐦 @thebyrdlab
Hi all: Brian Byrd, Ann Arbor, lurking this time & waiting for things to circle back to ... blood pressure! 😃 #NephJC
Tulun Sokit 🇲🇾 @tulunsokit
#nephjc mainly lurking today. Hi everyone
Kevin J. Fowler @gratefull080504
asking again #nephJC https://t.co/33ijoK5WN4
Poyan Mehr @poyanmehr
@gratefull080504 @NephJC no, definitely no #nephjc
Abraham E. Gracia R. @Abraham_RMI
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Scott Brimble @S_brimble
@silvishah Sorry am late, lurking no coi #NephJC
Nephrology Jrnl Club @NephJC
@gratefull080504 No they don't all progress. #nephjc
Poyan Mehr @poyanmehr
using the first time tchat,io and desktop, so trying to get handle on this #nephjc
Abraham E. Gracia R. @Abraham_RMI
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Patrick D Walker @trumidor
Pat Walker Arkana Labs lurking #nephjc
Nephrology Jrnl Club @NephJC
@S_brimble @silvishah welcome! #nephjc
Wings Implied @wingsimplied
RT @kidney_boy: RT if you had a crush on Olivia Newton John. Fav if you are too young to know who the hell that is. #nephjc
Dr. Paul Sufka @psufka
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Kevin J. Fowler @gratefull080504
What percent do? The article stated 18-35% do in 5 years #nephJC https://t.co/PkhBAhcfk0
Gates Colbert, MD @DoctorGates
@gratefull080504 Definitely not. Many #Vasculitis pts show great recovery, but still likely CKD from the AKI #NephJC
Dr. Paul Sufka @psufka
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Cathy Quinlan @KidneyCathy
Which implies that better AKI treatment is key https://t.co/hMSshj25Vm
Gerardo Alfaro @gerardoalfaromd
Práctico esquema para clasificar las vasculitis #enarm2017 #ENARM https://t.co/GKKaTn4E64
Dr. Paul Sufka @psufka
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Poyan Mehr @poyanmehr
RT @NephJC: Does anyone want to weigh in on the parallel group comparison methodology? #nephjc
Joel Topf, MD FACP @kidney_boy
@gratefull080504 Nope, this is a disease we are fairly good at but we lose some. #NephJC
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/bYPpe3xyt2
Scott Brimble @S_brimble
@poyanmehr @NephJC Simple design this is not #NephJC
Kevin J. Fowler @gratefull080504
Is the #ckd then stage 3, or 4? #nephJC https://t.co/hGO2JcR0Ja
Manish Rathi @manirath
#NephJC Manish Rathi from Chandigarh, India. No COI. https://t.co/RAONMmWUQe
Nephrology Jrnl Club @NephJC
Can a rheumatologist comment on the suitability of the Birmingham score for acute change? #nephJC #RheumJC
Joel Topf, MD FACP @kidney_boy
I thought the study design was appropriately conservative for a novel agent treating a manageable disease #nephjc
Nephrology Jrnl Club @NephJC
A huge shout out to our #rheumjc colleagues! Welcome to #nephjc
Joel Topf, MD FACP @kidney_boy
Yes, I had more problems with the low bar they established for an endpoint. #nephjc
Roger Rodby @NephRodby
Roger Rodby, too many COIs to count #NephJC
Kevin J. Fowler @gratefull080504
Didn't Celeste Lee Castillo have #vasculitis ? #nephJC https://t.co/ulxS3CJroi
Nephrology Jrnl Club @NephJC
The concern with complexity is always what is obscured. #nephjc https://t.co/W1eZnVkySs
Raul Reyna @raul_reyna
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Poyan Mehr @poyanmehr
@kidney_boy and most importantly. it was phase II - not meant to look for efficacy but safety #nephjc
Joel Topf, MD FACP @kidney_boy
RT @poyanmehr: @kidney_boy and most importantly. it was phase II - not meant to look for efficacy but safety #nephjc
Roger Rodby @NephRodby
I need a #nephpearls for parallel group issue #NephJC
Gates Colbert, MD @DoctorGates
@gratefull080504 It all depends on the eGFR where the patient stabilizes to stage the CKD. Unless you agree with the recent CJASN Aug issue #NephJC
Nephrology Jrnl Club @NephJC
@kidney_boy And the fact that baseline groups differed with respect to renal indices – crt, UACR, even eGFR #NephJC
Roger Rodby @NephRodby
Ali's @poyanmehr point is spot on #NephJC
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT
Joel Topf, MD FACP @kidney_boy
@NephJC @kidney_boy isn't that inevitable when you randomize 12 and 14 patients #nephjc
Nephrology Jrnl Club @NephJC
@NephRodby You might need to wait for #statsmadness #nephjc
Efraín J. Sánchez A. @efrasanchez
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Nephrology Jrnl Club @NephJC
RT @DoctorGates: @gratefull080504 It all depends on the eGFR where the patient stabilizes to stage the CKD. Unless you agree with t…
Kevin J. Fowler @gratefull080504
Why were there no US investigators + sites for the Phase 2 trial? #nephJC
Joel Topf, MD FACP @kidney_boy
@manirath thanks for coming #nephjc
Scott Brimble @S_brimble
Keep in mind also #PEXIVAS is evaluating 2 steroid tapering strategies in AAV. Results imminent via @lastwalsh #NephJC
Manish Rathi @manirath
@NephJC Though not qualified Rheumat. Think it's a reasonable good marker for acute change #NephJC
Nephrology Jrnl Club @NephJC
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Dr. Paul Sufka @psufka
@NephJC #nephJC BVAS is one of the most widely used measurement tools in research for systemic vasculitis. Well validated.
Kevin J. Fowler @gratefull080504
Is #vasculitis considered a #raredisease ? #nephJC
Joel Topf, MD FACP @kidney_boy
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Manish Rathi @manirath
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Nephrology Jrnl Club @NephJC
@poyanmehr @kidney_boy But endpoints and discussion message not focussed on safety but efficacy #nephjc
Roger Rodby @NephRodby
Form what I can tell, these are not the sick vasculitis patients I see with bad GN. not sure if results apply to my practice #NephJC
Poyan Mehr @poyanmehr
@gratefull080504 @kidney_boy @poyanmehr @kidney_boy because FDA more a challenging barrier than european counter part - that simple #nephjc
Dr. Paul Sufka @psufka
@NephJC #NephJC but keep in mind that any tool that tries to convert how a pt is doing to a number will always be flawed.
Poyan Mehr @poyanmehr
@gratefull080504 yes #nephjc
Manish Rathi @manirath
Nice #NephJC https://t.co/YNNTxLmBN8
Elías M. Coronado. @MaudeNarvarte
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Nephrology Jrnl Club @NephJC
@psufka And comparable to other scores #NephJC https://t.co/a7h7pK29LW
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@NephJC Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/ynoptpT5AP
Elías M. Coronado. @MaudeNarvarte
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Kevin J. Fowler @gratefull080504
Is the UK patient organization more active than US counterpart in #patientadvocacy? Where is the #patientvoice in the US? #hcldr https://t.co/dBHZ6Karp0
Kartik Kalra @kkalra_22
#nephjc
Arvind Canchi 🇮🇳 @arvindcanchi
RT @edgarvlermamd: @NephJC Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/ynoptpT5AP
Kevin J. Fowler @gratefull080504
Never have heard of a Phase 2 study without one US trial site Never #nephjc https://t.co/dBHZ6Ks2NA
Poyan Mehr @poyanmehr
@NephJC @kidney_boy that is where the confusion comes in. clearly not powered & designed for what we would like to see #nephjc
Manish Rathi @manirath
Changes in BVAS is good in assessing change in ds activity #NephJC https://t.co/3oU3gr9VtC
Nephrology Jrnl Club @NephJC
@NephRodby Sounds like they're more rheum than nephro #nephjc
Kevin J. Fowler @gratefull080504
Where is the US #patientvoice? #nephJC https://t.co/dBHZ6Ks2NA
Poyan Mehr @poyanmehr
@NephJC @kidney_boy but that is the very nature of early phase trial. to make sure no one dies, and that there is a signal to do ph3 #nephjc
Roger Rodby @NephRodby
I wonder if the Europeans diagnose vasculitis sooner than in the states? Or selection bias as a nephrologist I see the sickest #NephJC
Kartik Kalra @kkalra_22
#nephjc Hi Kartik Kalra Internal Medicine Resident. New Brunswick, NJ. No CoI.
Gates Colbert, MD @DoctorGates
Do you need #Meningococcal vaccination prior to #Avacopan administration a la #Eculizumab ? Asking for a friend. #nephjc
Nephrology Jrnl Club @NephJC
Excellent. Thanks @manirath https://t.co/9kKNGMoSFO
Pablo Garcia @PabloGarciaMD
@kkalra_22 Welcome #nephjc
Nottingham Eczema @eczemasupport
RT @gratefull080504: Is the UK patient organization more active than US counterpart in #patientadvocacy? Where is the #patientvoice in…
Joel Topf, MD FACP @kidney_boy
But then published in JASN? RT @NephJC: @NephRodby Sounds like they're more rheum than nephro #nephjc
Joel Topf, MD FACP @kidney_boy
RT @poyanmehr: @NephJC @kidney_boy but that is the very nature of early phase trial. to make sure no one dies, and that there is a signal t…
Nephrology Jrnl Club @NephJC
Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp
goingtomedschool @going2medschool
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Roger Rodby @NephRodby
@poyanmehr Yes not powered for that, but I would be reluctant to bail on steroids for RPGN #NephJC
Kevin J. Fowler @gratefull080504
@NephRodby : Why would that be? Please explain #nephJC https://t.co/g0r717E9Bn
Manish Rathi @manirath
#NephJC https://t.co/M7B9OFwufT
Poyan Mehr @poyanmehr
@NephRodby agree. average eGFR ~50, and borderline mostly microalbuminuria ?? #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@NephJC @NephRodby Not that there's anything wrong with that #NephJC https://t.co/6KcYw5w9zI
Kevin J. Fowler @gratefull080504
Exactly @kidney_boy ! Why invest in this study + publish in JASN if not planned for #nephrology #nephJC https://t.co/UEPg5xdBNE
Nephrology Jrnl Club @NephJC
@NephRodby Or referral bias? #nephjc
Poyan Mehr @poyanmehr
@kidney_boy @NephJC @NephRodby and that is why i am excited about.. we are catching on w trials and exploring new opportunities #nephjc
Nephrology Jrnl Club @NephJC
@gratefull080504 @NephRodby Someone with mild proteinuria might not be ref to nephro. Someone with AKI would be - so nephro see worse disease. #nephjc
Manish Rathi @manirath
@NephJC @poyanmehr @kidney_boy Agree. They shud just have focused on safety for time being. Efficacy is added advantage to be explored in further studies #NephJC
Poyan Mehr @poyanmehr
@NephRodby and if it is reproduced in a larger trial, powered for that endpoint? #nephjc
Kevin J. Fowler @gratefull080504
Asking again: Is #vasculitis a #raredisease ? #nephJC
Joel Topf, MD FACP @kidney_boy
This study is the tip of the spear. We are interested in it because it's a whole new promising drug. Very exciting. #nephjc
Nephrology Jrnl Club @NephJC
This study ran over 5 years – what else has changed in ANCA since then? Help a paed neph out - I don't see ANCA! #nephjc
Joel Topf, MD FACP @kidney_boy
@gratefull080504 I believe so #nephjc
Joel Topf, MD FACP @kidney_boy
@NephJC between Steps 1 and 2 and Step 3 rituximab came on the scene and I think it has convinced just about everyone. #nephjc
Kevin J. Fowler @gratefull080504
@kidney_boy : Are their other potential other applications in #kidneydisease ? #nephJC https://t.co/rUYTZg00lG
Manish Rathi @manirath
@NephJC Ritux has come in big way. Now the first line of tx #NephJC
Anitha Vijayan @VijayanMD
@poyanmehr @NephRodby phase III trial has started. Rheum colleague at Wash U is involved in that one. #nephJC
Joel Topf, MD FACP @kidney_boy
@gratefull080504 @kidney_boy Likely so, being a C5aR antagonist should make it useful in a number of compliments driven toxicities #nephjc
Roger Rodby @NephRodby
I think I see them later in dz. sicker RT @gratefull080504 @NephRodby : Why would that be? Please explain #nephJC https://t.co/1ALj9i3cQj
Nephrology Jrnl Club @NephJC
@gratefull080504 Yes overall but depends on the vasculitis. eg HSP not uncommon in childhood. #nephjc
Manish Rathi @manirath
@NephJC The same group, EUVAS has published so much abt Ritux #NephJC
Kevin J. Fowler @gratefull080504
The investigative compound did not lower proteinuria, correct? If correct,why ? #nephJC
Nephrology Jrnl Club @NephJC
@gratefull080504 @kidney_boy There are always other potential applications! #nephjc
Nephrology Jrnl Club @NephJC
RT @VijayanMD: @poyanmehr @NephRodby phase III trial has started. Rheum colleague at Wash U is involved in that one. #nephJC
Nephrology Jrnl Club @NephJC
RT @manirath: @NephJC Ritux has come in big way. Now the first line of tx #NephJC
Jeff Sparks @jeffsparks
RT @NephJC: A huge shout out to our #rheumjc colleagues! Welcome to #nephjc
Kevin J. Fowler @gratefull080504
@NephJC : such as ? #nephJC https://t.co/kK05h59XKG
Nephrology Jrnl Club @NephJC
Yes, but we should've been more systematic as a community early on. Bliss trial was a major wake-up. #nephjc https://t.co/utFCmMaaYb
Poyan Mehr @poyanmehr
@gratefull080504 I think advocacy groups are working to change that here.. not sure if for better or worse. 2 sided sword #nephjc
Dr. Paul Sufka @psufka
@NephJC #nephJC in the last 5 years, we’ve shown RTX=CYC for induction, and RTX best for maint. Anything new has to=RTX, since so well tolerated.
Kevin J. Fowler @gratefull080504
Is the @VasculitisFound on this chat? I hope so #nephJC
Jeff Sparks @jeffsparks
@NephJC It is what is typically used #NephJC #RheumJC
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@gratefull080504 ANCA Vasculitis #Rarediseases #NephJC 👉🏼 https://t.co/3zm2rCzUlL https://t.co/vArXiaQYMc
Nephrology Jrnl Club @NephJC
@gratefull080504 Every other vasculitis or complementopathy or nephrotic syndrome - we'll try anything there. #nephjc
Poyan Mehr @poyanmehr
@gratefull080504 some of it, as usual, is $$ driven #NephJC
Jeff Sparks @jeffsparks
RT @NephJC: Terrific summary (as always) from #nephpearls #nephjc https://t.co/FRGZuStKR5
Cathy Quinlan @KidneyCathy
RT @psufka: @NephJC #nephJC in the last 5 years, we’ve shown RTX=CYC for induction, and RTX best for maint. Anything new has to…
Roger Rodby @NephRodby
Anything that spares or avoids steroids has Holy Grail potential #NephJC
Liz McKinnon, MD @lildocliz1
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Kevin J. Fowler @gratefull080504
The current standard of care for #vasculitis looks awful for quality of life + becoming a #kidneytransplant candidate, etc, #nephJC
Gates Colbert, MD @DoctorGates
@NephJC @gratefull080504 Not uncommon, but still impressive. See Figure1 today in IG. https://t.co/vfwCusNhEv #NephJC
Gian Luca Erre @gian_erre
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Cathy Quinlan @KidneyCathy
REduced UACR according to table 2 #nephjc https://t.co/Cc2UKgb03B
Poyan Mehr @poyanmehr
RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC
Joel Topf, MD FACP @kidney_boy
RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC
Kevin J. Fowler @gratefull080504
This is partially explains #pharma interest in #vasculitis #raredisease #nephJC https://t.co/C9S7ubb6de
Nephrology Jrnl Club @NephJC
@gratefull080504 Patient perspective - generally positive towards GCs #nephJC Need more patient involvement in setting study outcomes @song_initiative
Roger Rodby @NephRodby
I could not find: All pts got CTX or RTX first, was pulse steroids given too? #NephJC
Kevin J. Fowler @gratefull080504
@KidneyCathy : I saw that but does it take a longer time to reduce proteinuria ? #nephJC https://t.co/rWzaBz4f1w
Nephrology Jrnl Club @NephJC
Does anyone know what Ava will cost? #NephJC
Poyan Mehr @poyanmehr
@gratefull080504 yes, but just that these little kids have nothing to do with ANCA.. but who cares when we are in selling business #nephjc
Joel Topf, MD FACP @kidney_boy
@NephJC how thick is your wallet? #nephjc
Anitha Vijayan @VijayanMD
@gratefull080504 @NephJC atypical HUS, C3 glomerulopathy #nephJC
Roger Rodby @NephRodby
@KidneyCathy reduced AER, but was low to start with, doesn't mean that much #NephJC
Poyan Mehr @poyanmehr
@NephJC depend on the phaseIII. sky is the limit... #nephjc
Kevin J. Fowler @gratefull080504
@NephJC : I saw Celeste suffer from long-term use of GC cumulative toxicity Where are the patients tonight? #nephJC https://t.co/8oWuQE3W1K
Nephrology Jrnl Club @NephJC
@NephRodby I couldn't find that either - surprised if they didn't but not mentioned. #nephjc
Roger Rodby @NephRodby
$ > rituxan < Acthar ? #NephJC
Edgar V. Lerma 🇵🇭 @edgarvlermamd
Monitoring of ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/rgHGtKPM6M https://t.co/GlfK1OTdaA
VOD-MD @vod_md
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Nalin Yadav @DrNalinYadav
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Roger Rodby @NephRodby
Pulse steroids is important, we have no idea just how long that lasts, my gut is that pulsing is like weeks of po steroids #NephJC
Kevin J. Fowler @gratefull080504
What is the primary endpoint for Phase III trial? #nephJC
Michelle Rheault @rheault_m
@gratefull080504 GPA incidence 0.5-10/million depending on diagnostic criteria and population #NephJC https://t.co/OFUS0JM1Y7 https://t.co/lA4rACw67R
Nalin Yadav @DrNalinYadav
RT @edgarvlermamd: Monitoring of ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/rgHGtKPM6M https://t.co/GlfK1OTdaA
Poyan Mehr @poyanmehr
@NephJC @NephRodby and i could not see the proportions of type of induction. did i miss?. #nephjc
Roger Rodby @NephRodby
No difference in adverse event % bit nature of adverse events very different #NephJC
Roger Rodby @NephRodby
@poyanmehr The devil is, always, in the details #NephJC
Kalyani Bambal @kriyer68
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Poyan Mehr @poyanmehr
RT @NephRodby: @poyanmehr The devil is, always, in the details #NephJC
Nephrology Jrnl Club @NephJC
@poyanmehr @NephRodby No - I can't find it either #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS
Roger Rodby @NephRodby
regardless, targeted therapies are the future #NephJC
Anitha Vijayan @VijayanMD
@gratefull080504 Induction of remission https://t.co/Kk28sxaQeK #nephJC
Poyan Mehr @poyanmehr
@gratefull080504 this is the link to trials registration site.. remission is the prim. outcome https://t.co/IVU1yEz4Xo #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https://t.co/xOF06Lcmdu
Roger Rodby @NephRodby
Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #NephJC
Nephrology Jrnl Club @NephJC
RT @rheault_m: @gratefull080504 GPA incidence 0.5-10/million depending on diagnostic criteria and population #NephJC
Arvind Canchi 🇮🇳 @arvindcanchi
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@NephRodby Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MyqE4 https://t.co/mPOpKDaM2y
Nephrology Jrnl Club @NephJC
@poyanmehr @gratefull080504 How is remission defined by BVS - 50% reduction or more? #nephjc
Kevin J. Fowler @gratefull080504
Amen #nephJC https://t.co/NtkTGaZCLt
Roger Rodby @NephRodby
Jayne, lead author, also lead of https://t.co/im2ajiRPqP, no stranger to vasculitis #NephJC
Nephrology Jrnl Club @NephJC
@NephRodby And both therapies have side effects and long term concerns. #nephjc
Nephrology Jrnl Club @NephJC
Love this diagram - it's going on my wall! #nephpearls #nephjc https://t.co/ZAEQreok23
george miguelito @georgemiguelito
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Roger Rodby @NephRodby
@NephJC I could draw that diagram in my sleep. #NephJC
Nephrology Jrnl Club @NephJC
At the risk of repetition - one of the core goals of #nephJC is to build a personal learning network so make sure to hit the follow button
Wings Implied @wingsimplied
RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC
Nephrology Jrnl Club @NephJC
So in summary, flawed methodology - interesting drug - potential to reduce GC use in early disease. Would you use it? #NephJC #nephjc
Poyan Mehr @poyanmehr
@NephJC why flawed methodology ? what did i miss? #nephjc
The Lewises @Lewis_Lab
RT @edgarvlermamd: @NephRodby Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MyqE4 https://t.co/…
Poyan Mehr @poyanmehr
@NephJC no way i would use it. we don't know yet if it is effective.. i would wait for larger trial #nephjc
Cathy Quinlan @KidneyCathy
@NephJC Would need to see some paeds data first and something beyond ANCA #nephjc
Nephrology Jrnl Club @NephJC
@poyanmehr methodology set up for safety but conclusions drawn re efficacy. Am I overcalling? #nephjc
Nathaniel Reisinger @nephrothaniel
I definitely have been lurking #nephJC the whole time instead of participating in the #NBLUniv happy hour!!
Edgar V. Lerma 🇵🇭 @edgarvlermamd
C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Roger Rodby @NephRodby
@NephJC "not ready for prime time" at least for me right now #NephJC
Manish Rathi @manirath
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Nephrology Jrnl Club @NephJC
@poyanmehr Feels like Ritux hit the wards with similarly limited data... #nephjc
Nephrology Jrnl Club @NephJC
Thanks you to everyone who took part and to all the lurkers, it’s been fun! #NephJC https://t.co/ya2bDr7kyf
Adriana Bello @adrianabello
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Manish Rathi @manirath
@NephJC Too early to say. Let it prove it's worth first 😀#NephJC
Poyan Mehr @poyanmehr
@NephJC well they need to show that it is safe, but they also need to show rationale for doing a larger study. i think they did. #nephjc
Joel Topf, MD FACP @kidney_boy
Great chat guys! #nephjc
Kevin J. Fowler @gratefull080504
@NephJC : Please explain why methodology is flawed? How can you make a prescribing decision of Phase 2 results? #nephJC https://t.co/aUle62xCiY
Gates Colbert, MD @DoctorGates
#Avacopan - exciting drug, interesting article previewing its potential to the #Vasculitis world with this publication. Will see! #nephjc
Mayuri Trivedi @MayuriTrivedi80
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Joel Topf, MD FACP @kidney_boy
But ready for a phase 3 for sure! RT @NephRodby: @NephJC "not ready for prime time" at least for me right now #NephJC
Nephrology Jrnl Club @NephJC
RT @poyanmehr: @NephJC well they need to show that it is safe, but they also need to show rationale for doing a larger study. i think they…
Mayuri Trivedi @MayuriTrivedi80
RT @NephJC: Love this diagram - it's going on my wall! #nephpearls #nephjc https://t.co/ZAEQreok23
Mayuri Trivedi @MayuriTrivedi80
RT @edgarvlermamd: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS
Poyan Mehr @poyanmehr
@NephJC but i agree, that the manuscript could have been more clear on the nature and purpose of trial #nephjc
Kevin J. Fowler @gratefull080504
Key question: How can this potential treatment improve the #vasculitis patient journey? What is the potential value prop? #nephJC https://t.co/aUle62xCiY
Kevin J. Fowler @gratefull080504
@poyanmehr : I have the same question #nephJC https://t.co/sfMWvIUlil
Joel Topf, MD FACP @kidney_boy
Thanks Cathy, great job hosting from down under! I liked how your tweets went counter-clockwise #nephjc
Edgar V. Lerma 🇵🇭 @edgarvlermamd
@NephJC Agree with @NephRodby Not ready for prime time #NephJC https://t.co/Qm3vy0cHSu
Roger Rodby @NephRodby
@kidney_boy For sure needs phase 3, wish patients were sicker, but they probably won't be, not a neph trial #NephJC
Mitochondrial Eve @BrowofJustice
RT @kidney_boy: Thanks Cathy, great job hosting from down under! I liked how your tweets went counter-clockwise #nephjc
أحبك ربي . @uaeforever1
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Nephrology Jrnl Club @NephJC
@gratefull080504 MAybe I'm overstating but I don't think you can draw conclusions about efficacy from a trial set up to assess safety. #nephjc
Mayuri Trivedi @MayuriTrivedi80
RT @NephRodby: Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #Neph
Kevin J. Fowler @gratefull080504
Is a medication ever ready for primetime after only Phase 2? #nephJC https://t.co/6r26ErXIPR
Kevin J. Fowler @gratefull080504
@NephJC: Agreed but efficacy was not the primary endpoint, correct? #nephJC https://t.co/iKdeZbvwrh
Manish Rathi @manirath
@edgarvlermamd @MayuriTrivedi80 I think renal involvement & it's severity is also one of the strong predictor of outcome #NephJC @NephJC
Nephrology Jrnl Club @NephJC
Another potential therapy in the future armory. More data needed. Good to see targeted therapies. #nephjc https://t.co/w9ItQEgZyz
Nephrology Jrnl Club @NephJC
RT @NephRodby: @kidney_boy For sure needs phase 3, wish patients were sicker, but they probably won't be, not a neph trial #NephJC
Kevin J. Fowler @gratefull080504
@NephJC : Without a doubt! #nephJC https://t.co/R9WPhsXCBi
Manish Rathi @manirath
Nice interaction. Learnt a lot. Thanks #NephJC https://t.co/frVSW0xfYZ
Manish Rathi @manirath
RT @NephJC: Another potential therapy in the future armory. More data needed. Good to see targeted therapies. #nephjc https://t.co/w9ItQEgZ…
Roger Rodby @NephRodby
No wuckers , Hoo roo/Oooroo , Cheers mates, https://t.co/aiQ03VXnec #NephJC
Nephrology Jrnl Club @NephJC
Yes. We'll have to wait for phase 3. However abstract conc (all that will b read by most) states effective in replacing GCs. #nephjc https://t.co/FJ7CmSvxkZ
Gerardo Alfaro @gerardoalfaromd
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Kevin J. Fowler @gratefull080504
@NephJC : Based upon potential improvement in quality of life safety #nephJC https://t.co/yYdZTLEmeR
ISN Education @ISNeducation
@edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Joel Topf, MD FACP @kidney_boy
The numbers: 307 Tweets. 61 Participants. August 7th 2017. More #NephJC 📊 here https://t.co/T5dkn5tEE6 via @symplur
Cathy Quinlan @KidneyCathy
Thx to #nephjc for showing me what parenting octuplets would be like! Now Grand Rounds with the amazing Laila! @RCHMelbourne @MCRI_for_kids
Roger Rodby @NephRodby
RT @poyanmehr: @gratefull080504 this is the link to trials registration site.. remission is the prim. outcome https://t.co/IVU1yEz4Xo #neph
Didem Saygin, MD @didemsayginmd
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Divya Bajpai 🇮🇳 @divyaa24
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Manish Rathi @manirath
Haha... What a way to remember #NephJC @nainamdar @therealvenky @srikanthnephro @SreejithDr https://t.co/RCPX5TrPc7
Sanjeev Nair @Nair_Sanj
Looks like I missed out on a great #nephjc due to unexpected baby sitting duties. Ah well next time..
Federico Garcia @fedepjam
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Federico Garcia @fedepjam
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Ernesto LopezAlmaraz @kidney_doctor
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Elías M. Coronado. @MaudeNarvarte
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Dr. Jose Astudillo @jj_astudillo
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Dr. Jose Astudillo @jj_astudillo
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Dr. Jose Astudillo @jj_astudillo
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Abraham E. Gracia R. @Abraham_RMI
RT @edgarvlermamd: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS
Samir Nangia MD CPE @SamirNangia
RT @NBLUniv: Visual abstracts #nephJC #NBLUniv https://t.co/agFgmCGgPj
Abraham E. Gracia R. @Abraham_RMI
RT @edgarvlermamd: Monitoring of ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/rgHGtKPM6M https://t.co/GlfK1OTdaA
Arvind Canchi 🇮🇳 @arvindcanchi
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Manish Rathi @manirath
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
#NephJC content from Twitter.